Recombinant human leukemia inhibitory factor does not improve implantation and pregnancy outcomes after assisted reproductive techniques in women with recurrent unexplained implantation failure

Fertil Steril. 2009 Apr;91(4 Suppl):1445-7. doi: 10.1016/j.fertnstert.2008.06.047. Epub 2008 Aug 16.

Authors

Peter R Brinsden¹, Veronica Alam, Beatrice de Moustier, Patrick Engrand

Affiliation

¹ Bourn Hall Clinic, Bourn, Cambridge, Cambridgeshire, United Kingdom. peter@brinsden.net

PMID: 18710712
DOI: 10.1016/j.fertnstert.2008.06.047

Abstract

In this randomized, double-blind, placebo-controlled, multicenter study, women (n = 149) with a history of at least two unexplained implantation failures after assisted reproductive techniques received recombinant human leukemia inhibitory factor, 150 microg SC twice daily for 7 days, or placebo. The clinical pregnancy rate after ET was significantly lower in patients receiving recombinant human leukemia inhibitory factor than in those receiving placebo (17.6% vs. 34.0%, respectively).

Publication types

Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Double-Blind Method
Embryo Transfer / methods
Embryonic Development / drug effects*
Endpoint Determination
Female
Humans
Infertility, Female / therapy*
Leukemia Inhibitory Factor / pharmacology*
Pregnancy
Pregnancy Outcome*
Pregnancy Rate
Recombinant Proteins / pharmacology*
Reproductive Techniques, Assisted*
Treatment Failure
Treatment Outcome

Substances

LIF protein, human
Leukemia Inhibitory Factor
Recombinant Proteins